What is the clinical efficacy of anamorelin in cancer treatment?

The clinical efficacy of Anamorelin (Anamorelin) in cancer treatment is mainly reflected in the improvement of cancer cachexia (CC). As a new type of oral small molecule drug, anamorelin stimulates the appetite center by activating ghrelin receptors, thereby increasing the patient's appetite and weight, improving muscle mass, and improving quality of life.

Multiple clinical trials have confirmed the effectiveness of anamorelin in the treatment of cancer cachexia. For example, a multicenter, placebo-controlled, randomized, double-blind, parallel-group study (ONO-7643-04 study) in patients with non-small cell lung cancer (NSCLC) showed that patients treated with anamorelin experienced significant improvements in body weight, muscle mass, and appetite compared with placebo. In addition, another multicenter, open-label, uncontrolled phase III study (ONO-7643-05 study) conducted in patients with colorectal, gastric, and pancreatic cancer also found similar results.

Many patients gain weight after receiving anamorelin, which is important in patients with cancer cachexia because weight loss is often accompanied by malnutrition and muscle wasting. Anamorelin can promote muscle growth and reduce muscle consumption, which is of great significance for improving patients' physical strength and quality of life.

By activating the ghrelin receptor, anamorelin can significantly enhance the patient's appetite, allowing the patient to consume more nutrients, thus improving malnutrition.

Anamorelin demonstrated good safety and tolerability in clinical trials. Although some patients may experience side effects such as nausea, vomiting, and diarrhea, most side effects are mild to moderate and can be effectively alleviated by adjusting the dose or taking supportive care. In addition, doctors will conduct a comprehensive assessment of the patient before taking the drug to ensure that the patient is suitable for using anamorelin, and closely monitor the patient's physical condition and drug response.